Invention Grant
- Patent Title: Fusion protein binding to CD47 protein and application thereof
-
Application No.: US17048202Application Date: 2019-04-16
-
Publication No.: US11891423B2Publication Date: 2024-02-06
- Inventor: Ming Lv , Xiaoran Ding , Shiwei Miao , Bin Tan , Xuegong Wang
- Applicant: HANGZHOU SUMGEN BIOTECH CO., LTD. , SUMGEN MAB (BEIJING) BIOTECH CO., LTD.
- Applicant Address: CN Zhejiang
- Assignee: HANGZHOU SUMGEN BIOTECH CO., LTD.,SUMGEN MAB (BEIJING) BIOTECH CO., LTD.
- Current Assignee: HANGZHOU SUMGEN BIOTECH CO., LTD.,SUMGEN MAB (BEIJING) BIOTECH CO., LTD.
- Current Assignee Address: CN Zhejiang; CN Beijing
- Agency: Honigman LLP
- Agent Thomas A. Wootton, Esq.; Jonathan P. O'Brien
- Priority: CN 1810343482.9 2018.04.17
- International Application: PCT/CN2019/082863 2019.04.16
- International Announcement: WO2019/201236A 2019.10.24
- Date entered country: 2020-10-16
- Main IPC: C07K16/46
- IPC: C07K16/46 ; C07K19/00 ; C07K14/00 ; A61K39/395 ; C07K14/47 ; A61P35/00 ; A61K38/00 ; A61K39/00
Abstract:
Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10−8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRPα without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.
Public/Granted literature
- US20210171593A1 FUSION PROTEIN BINDING TO CD47 PROTEIN AND APPLICATION THEREOF Public/Granted day:2021-06-10
Information query
